Bacterial infections epidemiology and factors associated with multidrug resistance in the northern region of Ghana.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      Bacterial Infections*/drug therapy ; Bacterial Infections*/epidemiology ; Bacterial Infections*/microbiology; Humans ; Ghana/epidemiology ; Retrospective Studies ; Cross-Sectional Studies ; Microbial Sensitivity Tests ; Bacteria/genetics ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Drug Resistance, Multiple ; Drug Resistance, Multiple, Bacterial
    • Abstract:
      Bacterial infections caused by multidrug resistant organisms are a major global threat. There is still a knowledge gap on this situation in the Northern Region of Ghana. This study determined the prevalence and resistance profile of bacterial infections. It also identified factors associated with multidrug resistance in the study area. This was a retrospective cross-sectional design and it analyzed data from the samples received at the Tamale Zonal Public Health Reference Laboratory from June 2018 to May 2022. The data were analyzed using the R software version 4.2.0. Univariate and multivariable binary logistic regression analyses were used to determine the factors associated with multidrug resistance. The samples included all specimen types possible. The specimens were collected for the purpose of clinical bacteriology diagnostics. Overall a total of 1222 isolates were obtained. The three (3) main bacteria responsible for infections were: Klebsiella spp. (27%), Moraxella spp. (22%), Escherichia spp. (16%). High resistance levels were found against the tested antibiotics and about 41.60% of the bacterial strains isolated were multidrug resistant. Hospitalization was associated with multidrug resistance in univariate (COR 1.96; 95% CI 1.43-2.71; P-value < 0.001) and multivariable analyses (AOR 1.78; 95% CI 1.28-2.49; P-value < 0.001). There is the need for further research on the molecular epidemiology of antibiotic resistance genes in the study area to effectively control the spread of multidrug resistant pathogens. In addition, efforts to build the capacity of health professionals on infection prevention and control as well as diagnostic and antimicrobial stewardship needs urgent attention.
      (© 2022. The Author(s).)
    • References:
      Clin Microbiol Rev. 2018 Feb 14;31(2):. (PMID: 29444952)
      Am J Clin Pathol. 1966 Apr;45(4):493-6. (PMID: 5325707)
      BMC Microbiol. 2020 Aug 14;20(1):253. (PMID: 32795260)
      Open Forum Infect Dis. 2020 Mar 28;7(4):ofaa109. (PMID: 32373647)
      Bull World Health Organ. 2017 Aug 01;95(8):599-603. (PMID: 28804172)
      Ann Clin Microbiol Antimicrob. 2021 Mar 11;20(1):16. (PMID: 33706775)
      Antimicrob Resist Infect Control. 2019 Jun 18;8:104. (PMID: 31244995)
      Clin Lab. 2020 Jul 1;66(7):. (PMID: 32658423)
      Lancet. 2018 May 12;391(10133):1873-1875. (PMID: 29550031)
      Nat Rev Microbiol. 2022 May;20(5):257-269. (PMID: 34737424)
      Int J Infect Dis. 2020 Feb;91:207-209. (PMID: 31770618)
      BMC Res Notes. 2018 Jul 13;11(1):471. (PMID: 30005695)
      Int J Food Sci. 2020 Nov 12;2020:8877196. (PMID: 33274191)
      AIMS Microbiol. 2021 Feb 3;7(1):75-95. (PMID: 33659770)
      Infect Drug Resist. 2022 Feb 17;15:475-490. (PMID: 35210791)
      Diagn Microbiol Infect Dis. 2016 Apr;84(4):328-33. (PMID: 26830052)
      JAMA Netw Open. 2021 Jul 1;4(7):e2116555. (PMID: 34269807)
      Salud Publica Mex. 2018 Mar-Apr;60(2):151-157. (PMID: 29738654)
      Am J Infect Control. 2017 Oct 1;45(10):1069-1073. (PMID: 28803661)
      Antibiotics (Basel). 2021 Feb 18;10(2):. (PMID: 33670659)
      Environ Health Insights. 2022 Feb 14;16:11786302221078117. (PMID: 35185334)
      Molecules. 2020 Mar 16;25(6):. (PMID: 32187986)
      FEMS Microbiol Rev. 2017 May 1;41(3):252-275. (PMID: 28521338)
      Med Pharm Rep. 2020 Jul;93(3):231-240. (PMID: 32832887)
      Infect Drug Resist. 2021 Jun 14;14:2201-2212. (PMID: 34163185)
      Infect Drug Resist. 2015 Nov 18;8:379-89. (PMID: 26604806)
      Epidemiol Health. 2019;41:e2019014. (PMID: 31010280)
      BMJ Open. 2017 Nov 08;7(11):e016251. (PMID: 29122787)
      Antibiotics (Basel). 2021 Oct 08;10(10):. (PMID: 34680802)
      Trop Med Infect Dis. 2019 Sep 03;4(3):. (PMID: 31484298)
      BMC Infect Dis. 2020 Nov 25;20(1):890. (PMID: 33238903)
      Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0218321. (PMID: 35007133)
      Clin Microbiol Rev. 2020 May 13;33(3):. (PMID: 32404435)
      Clin Microbiol Infect. 2012 Mar;18(3):268-81. (PMID: 21793988)
      Antimicrob Resist Infect Control. 2018 Mar 9;7:37. (PMID: 29541448)
      Int J Environ Res Public Health. 2022 Jan 18;19(3):. (PMID: 35162062)
      Infect Drug Resist. 2018 Oct 10;11:1645-1658. (PMID: 30349322)
      Infect Drug Resist. 2018 Nov 15;11:2321-2333. (PMID: 30532565)
      J Trop Med. 2019 Sep 19;2019:6750864. (PMID: 31641359)
      Clin Infect Dis. 2021 Dec 1;73(Suppl_4):S308-S315. (PMID: 34850837)
      Gastrointest Endosc Clin N Am. 2020 Oct;30(4):637-652. (PMID: 32891222)
      Nat Rev Urol. 2015 Oct;12(10):570-84. (PMID: 26334085)
      Eur J Clin Microbiol Infect Dis. 2018 Sep;37(9):1627-1636. (PMID: 29948360)
      Intensive Care Med. 2020 Aug;46(8):1536-1551. (PMID: 32591853)
      Microb Genom. 2018 Jul;4(7):. (PMID: 30035710)
      Microb Drug Resist. 2021 Jan;27(1):18-24. (PMID: 32522076)
      J Glob Antimicrob Resist. 2021 Jun;25:82-86. (PMID: 33662642)
      Am J Infect Control. 2018 Mar;46(3):341-345. (PMID: 29102426)
      Lancet Infect Dis. 2018 Mar;18(3):318-327. (PMID: 29276051)
      Infect Disord Drug Targets. 2021;21(4):595-602. (PMID: 32729432)
      Trends Microbiol. 2016 Dec;24(12):944-956. (PMID: 27742466)
      BMC Res Notes. 2018 Apr 25;11(1):254. (PMID: 29695265)
      BMC Microbiol. 2022 Jul 21;22(1):180. (PMID: 35864456)
      BMC Infect Dis. 2021 Jan 23;21(1):109. (PMID: 33485326)
      One Health Outlook. 2020 Aug 18;2:12. (PMID: 33829133)
      Germs. 2020 Dec 28;10(4):310-321. (PMID: 33489946)
      Am J Infect Control. 2019 Dec;47(12):1479-1483. (PMID: 31331712)
      J Antimicrob Chemother. 2016 Jul;71(7):1800-6. (PMID: 27040304)
      Ann Clin Microbiol Antimicrob. 2016 May 04;15:29. (PMID: 27145868)
      Med Clin North Am. 2019 May;103(3):487-501. (PMID: 30955516)
      Antibiotics (Basel). 2022 May 19;11(5):. (PMID: 35625333)
      Pan Afr Med J. 2020 Feb 12;35:37. (PMID: 32499853)
      Pan Afr Med J. 2020 Jan 15;35:12. (PMID: 32341733)
      J Infect Public Health. 2020 Apr;13(4):651-656. (PMID: 31522967)
      Open Forum Infect Dis. 2019 Nov 22;6(12):ofz503. (PMID: 31844639)
      Lancet Infect Dis. 2020 Apr;20(4):e51-e60. (PMID: 32059790)
      J Glob Antimicrob Resist. 2019 Dec;19:154-160. (PMID: 31112804)
      Chin Med J (Engl). 2020 Sep 20;133(18):2250-2252. (PMID: 32804738)
    • Accession Number:
      0 (Anti-Bacterial Agents)
    • Publication Date:
      Date Created: 20221221 Date Completed: 20221223 Latest Revision: 20230122
    • Publication Date:
      20230123
    • Accession Number:
      PMC9772187
    • Accession Number:
      10.1038/s41598-022-26547-7
    • Accession Number:
      36543904